NZ703560A - Method for activating helper t cell - Google Patents

Method for activating helper t cell

Info

Publication number
NZ703560A
NZ703560A NZ703560A NZ70356011A NZ703560A NZ 703560 A NZ703560 A NZ 703560A NZ 703560 A NZ703560 A NZ 703560A NZ 70356011 A NZ70356011 A NZ 70356011A NZ 703560 A NZ703560 A NZ 703560A
Authority
NZ
New Zealand
Prior art keywords
hla
drb1
peptide
seq
molecule
Prior art date
Application number
NZ703560A
Other languages
English (en)
Inventor
Haruo Sugiyama
Shinji Sogo
Masayoshi Sato
Ryuki Kitamoto
Yoshihiro Goto
Original Assignee
Otsuka Pharma Co Ltd
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd, Int Inst Cancer Immunology Inc filed Critical Otsuka Pharma Co Ltd
Publication of NZ703560A publication Critical patent/NZ703560A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ703560A 2010-10-05 2011-10-04 Method for activating helper t cell NZ703560A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010225806 2010-10-05
NZ609460A NZ609460A (en) 2010-10-05 2011-10-04 Method for activating helper t cell

Publications (1)

Publication Number Publication Date
NZ703560A true NZ703560A (en) 2016-11-25

Family

ID=45927725

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ609460A NZ609460A (en) 2010-10-05 2011-10-04 Method for activating helper t cell
NZ703560A NZ703560A (en) 2010-10-05 2011-10-04 Method for activating helper t cell

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ609460A NZ609460A (en) 2010-10-05 2011-10-04 Method for activating helper t cell

Country Status (21)

Country Link
US (2) US10654892B2 (OSRAM)
EP (1) EP2626418B8 (OSRAM)
JP (3) JP6134139B2 (OSRAM)
KR (3) KR102171794B1 (OSRAM)
CN (2) CN105802910A (OSRAM)
AR (1) AR083295A1 (OSRAM)
AU (1) AU2011313327B2 (OSRAM)
BR (1) BR112013008230A2 (OSRAM)
CA (1) CA2813557C (OSRAM)
CO (1) CO6710946A2 (OSRAM)
EA (1) EA037547B1 (OSRAM)
ES (1) ES2849187T3 (OSRAM)
IL (2) IL225536B (OSRAM)
MX (2) MX361299B (OSRAM)
MY (1) MY170306A (OSRAM)
NZ (2) NZ609460A (OSRAM)
PH (1) PH12013500654A1 (OSRAM)
SG (3) SG10202108581TA (OSRAM)
TW (2) TWI608099B (OSRAM)
WO (1) WO2012046730A1 (OSRAM)
ZA (1) ZA201303056B (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2071028T3 (pl) 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
MY158219A (en) 2007-02-27 2016-09-15 Int Inst Cancer Immunology Inc Method for activation of helper t cell and composition for use in the method
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
MX361299B (es) * 2010-10-05 2018-11-30 Otsuka Pharmaceutical Co Ltd Star Metodo para activar celulas auxiliares.
EP3520810A3 (en) 2012-01-13 2019-11-06 Memorial Sloan-Kettering Cancer Center Immunogenic wt1 peptides and use thereof
JP6535463B2 (ja) * 2012-09-12 2019-06-26 株式会社癌免疫研究所 抗原特異的ヘルパーｔ細胞レセプター遺伝子
BR112015013697A2 (pt) * 2012-12-17 2017-11-14 Univ Osaka método para ativar célula t auxiliar
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
PL2945647T3 (pl) 2013-01-15 2021-03-08 Memorial Sloan Kettering Cancer Center Immunogenne peptydy wt-1 i sposoby ich zastosowania
EP3461493A1 (en) 2013-03-29 2019-04-03 Sumitomo Dainippon Pharma Co., Ltd. Wt1 antigen peptide conjugate vaccine
EP3112378B1 (en) * 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
CA2974066C (en) 2014-12-25 2025-05-06 International Institute Of Cancer Immunology, Inc. METHOD FOR MODIFYING A T LYMPHOCYTE POPULATION
CN106565836B (zh) * 2015-10-10 2020-08-18 中国科学院广州生物医药与健康研究院 高亲和力的可溶性pdl-1分子
JP6994201B2 (ja) 2016-11-09 2022-02-21 国立大学法人大阪大学 Ｔ細胞集団の改変方法
EP3549957A4 (en) * 2016-11-30 2020-08-05 Sumitomo Dainippon Pharma Co., Ltd. AUXILIARY PEPTIDE WT1, AND COMBINATION OF DUDIT PEPTIDE AND CONJUGATE PEPTIDE ANTIGENIC FOR CANCER
WO2019131722A1 (ja) * 2017-12-27 2019-07-04 大日本住友製薬株式会社 Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物
JP6857930B2 (ja) * 2018-02-15 2021-04-14 国立大学法人旭川医科大学 がん抗原ペプチド
CA3109496A1 (en) * 2018-08-22 2020-02-27 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726288A (en) 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
CA2337743C (en) 1998-07-31 2015-07-07 Yoshihiro Oka Tumor antigen based on products of the tumor suppressor gene wt1
BR9914116A (pt) 1998-09-30 2002-01-15 Corixa Corp Composições e métodos para imunoterapia especìfica de wt1
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AU2001247220A1 (en) 2000-02-22 2001-09-03 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
CN1281625C (zh) 2001-03-22 2006-10-25 株式会社癌免疫研究所 经修饰的wt1肽
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
CN1320923C (zh) 2001-06-29 2007-06-13 中外制药株式会社 含有基于癌抑制基因wt1的产物的癌抗原和阳离子脂质体的癌疫苗
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
EP1447092A4 (en) 2001-09-28 2007-07-11 Haruo Sugiyama METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
JP4365784B2 (ja) 2002-06-12 2009-11-18 株式会社癌免疫研究所 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
ES2538486T3 (es) 2002-09-12 2015-06-22 International Institute Of Cancer Immunology, Inc. Preparación de péptidos antigénicos contra el cáncer
EP1548028B1 (en) 2002-09-20 2009-09-09 International Institute of Cancer Immunology, Inc. Substituted type peptides of wt1
CA2513701C (en) 2003-01-15 2013-06-18 Haruo Sugiyama Dimerized peptide
EP2343083B1 (en) 2003-06-27 2014-01-15 International Institute of Cancer Immunology, Inc. Method of diagnosing cancer comprising the measurement of WT1-specific CTL precursor cells
PL2071028T3 (pl) 2003-11-05 2012-06-29 Int Inst Cancer Immunology Inc Pochodzący z WT1 peptyd antygenowy wiążący się z HLA-DR
DK2186896T3 (en) 2004-03-31 2015-12-21 Int Inst Cancer Immunology Inc Cancer antigen peptides derived from WT1
US7608769B2 (en) * 2004-05-12 2009-10-27 First Act, Inc. Packaged drum set
JP4719876B2 (ja) 2005-04-04 2011-07-06 国立大学法人愛媛大学 Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
WO2007063903A1 (ja) 2005-11-30 2007-06-07 International Institute Of Cancer Immunology, Inc. 新規ペプチド化合物
US7420880B2 (en) 2005-12-29 2008-09-02 Timex Group B.V. Multimode electronic device with calibrating/setting mechanism
CN102250211A (zh) 2006-02-22 2011-11-23 株式会社癌免疫研究所 Hla-a*3303限制性wt1肽和包含此肽的药物组合物
EP2010209B1 (en) 2006-04-10 2016-06-15 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
SI2341142T1 (sl) * 2006-12-28 2015-03-31 International Institute Of Cancer Immunology, Inc. HLA-A*1101-omejen WT1 peptid in farmacevtski sestavek, ki ga vsebuje
MY158219A (en) 2007-02-27 2016-09-15 Int Inst Cancer Immunology Inc Method for activation of helper t cell and composition for use in the method
EP2116596A4 (en) 2007-03-05 2010-04-07 Int Inst Cancer Immunology Inc L-CELL RECEPTOR GENE SPECIFIC TO A CANCER ANTIGEN, PEPTIDE CODED BY THE GENE AND THEIR USE
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
MX361299B (es) * 2010-10-05 2018-11-30 Otsuka Pharmaceutical Co Ltd Star Metodo para activar celulas auxiliares.
BR112015013697A2 (pt) 2012-12-17 2017-11-14 Univ Osaka método para ativar célula t auxiliar

Also Published As

Publication number Publication date
JPWO2012046730A1 (ja) 2014-02-24
KR102171794B1 (ko) 2020-10-29
CN103298928A (zh) 2013-09-11
IL245440A0 (en) 2016-06-30
CO6710946A2 (es) 2013-07-15
EP2626418B1 (en) 2020-12-09
PH12013500654A1 (en) 2013-05-06
SG10201508252PA (en) 2015-11-27
MX2018008436A (es) 2021-12-08
IL225536A0 (en) 2013-06-27
JP6134139B2 (ja) 2017-05-24
MX361299B (es) 2018-11-30
TWI608099B (zh) 2017-12-11
TW201623616A (zh) 2016-07-01
US10654892B2 (en) 2020-05-19
NZ609460A (en) 2015-07-31
CN103298928B (zh) 2016-04-20
US20130266958A1 (en) 2013-10-10
US12415833B2 (en) 2025-09-16
IL225536B (en) 2019-03-31
JP6298101B2 (ja) 2018-03-20
KR20140009168A (ko) 2014-01-22
AU2011313327B2 (en) 2015-10-22
BR112013008230A2 (pt) 2016-06-14
AU2011313327A1 (en) 2013-05-02
EP2626418A4 (en) 2014-02-19
JP2017006120A (ja) 2017-01-12
ES2849187T3 (es) 2021-08-16
SG10202108581TA (en) 2021-09-29
KR102079480B1 (ko) 2020-02-19
ZA201303056B (en) 2013-12-23
CA2813557A1 (en) 2012-04-12
EA201390509A1 (ru) 2013-08-30
SG189287A1 (en) 2013-05-31
TW201217525A (en) 2012-05-01
EA037547B1 (ru) 2021-04-12
EP2626418B8 (en) 2021-03-24
CA2813557C (en) 2021-05-04
KR20190034359A (ko) 2019-04-01
EP2626418A1 (en) 2013-08-14
AR083295A1 (es) 2013-02-13
MY170306A (en) 2019-07-17
MX2013003884A (es) 2013-07-05
US20200354405A1 (en) 2020-11-12
KR20200018738A (ko) 2020-02-19
WO2012046730A1 (ja) 2012-04-12
CN105802910A (zh) 2016-07-27
JP2018093870A (ja) 2018-06-21

Similar Documents

Publication Publication Date Title
NZ703560A (en) Method for activating helper t cell
NZ600732A (en) Oxyntomodulin peptide analogue
SG194707A1 (en) Amino acid sequence presenting fusion polypeptide and its use
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
NZ600731A (en) Oxyntomodulin peptide analogue
CY1118664T1 (el) Απομονωμενο πολυπεπτιδιο των πρωτεϊνων τοξινης α και τοξινης β toy c. difficile και χρησεις αυτου
NZ597692A (en) Anti-IGF antibodies
NZ708990A (en) Method for activating helper t cell
MX2014000210A (es) Peptidos procoagulantes y sus derivados, y usos para estos.
RU2009128979A (ru) Hla*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция
NZ597923A (en) Protein glycosylation
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
NZ601591A (en) Methods for treating pancreatic cancer
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
NZ599590A (en) Factor involved in latent infection with herpesvirus, and use thereof
WO2010007144A3 (en) Mutated netrin-4 proteins, fragments thereof and their uses as drugs
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
NZ586074A (en) LCLRP peptides, constructs and uses thereof
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
CN104650185A (zh) 一条与猪瘟e0蛋白相结合的多肽序列及其应用
Lu et al. A new strategy for synthesis of branched cyclic peptide by Asn side-chain hydrazide ligation
EA201590431A1 (ru) Пшеница с новыми аллелями rht-b1
JP2013522174A5 (OSRAM)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 04 OCT 2018 BY HENRY HUGHES IP LIMITED

Effective date: 20170406

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2019 BY HENRY HUGHES IP LIMITED

Effective date: 20180911

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2020 BY HENRY HUGHES IP LIMITED

Effective date: 20190827

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2021 BY HENRY HUGHES IP LIMITED

Effective date: 20200915

ASS Change of ownership

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, , JP

Effective date: 20210317

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2022 BY HENRY HUGHES IP LIMITED

Effective date: 20210927

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2023 BY HENRY HUGHES IP LIMITED

Effective date: 20220920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2024 BY HENRY HUGHES IP LIMITED

Effective date: 20230919

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 OCT 2025 BY HENRY HUGHES IP LIMITED

Effective date: 20241002